Literature
- Bast R. C., Hunter V., Knapp R. C. Pros and cons of gynecologic tumor markers. Cancer 1987; 60: 1984–1992
- Schilthuis M. S., Aalders J. G., Bouma J., Kooi H., Fleuren G. J., Willemse P. H. B., de Bruijn H. W. A. Serum CA 125 levels in epithelial ovarian cancers: Relation with findings at second-look operations and their role in the detection of tumor recurrence. Br. J. Obstet. Gynaecol 1987; 94: 202–207
- Fleuren G. J., Nap M., Aalders J. G. B., Trimbos de Bruijn H. W. A. Explanations for the limited correlation between tumor CA 125 content and serum CA 125 antigen levels in patients with ovarian cancer. Cancer 1987; 60: 2437–2442
- Duk J. M., Aalders J. G., Fleuren G. J. H., de Bruijn W. A. CA 125, an useful marker in endometrial carcinoma. Am. J. Obstet. Gynecol 1986; 155: 1097–1102
- de Bruijn H. W. A., Aalders J. G., Kauer F. M., Duk J. M., Fleuren G. J. The biodistribution of CA 125 in the female genital tract. New tumor markers and their monoclonal antibodies, R. Klapdor. Georg Thieme Verlag, Stuttgart 1987; 334–341
- SCC Antigen in the management of squamous cell carcinoma, H. H. Kato, W. A. de Bruijn, W. Ebert, R. H. Herberman, J. T. Johnson. Excerpta Medica, New York 1987; 239, ISBN 444-01351-2